OTCPK:CBDS

Stock Analysis Report

Executive Summary

Cannabis Sativa, Inc., through its subsidiaries, develops, manufactures, and sells herbal based skin care products in the United States and internationally.

Snowflake

Fundamentals

Mediocre balance sheet with weak fundamentals.

Risks

  • Cannabis Sativa has significant price volatility in the past 3 months.
  • Cannabis Sativa is not covered by any analysts.

Share Price & News

How has Cannabis Sativa's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.8%

CBDS

-0.04%

US Healthcare

-0.6%

US Market


1 Year Return

-80.4%

CBDS

-9.1%

US Healthcare

0.7%

US Market

CBDS underperformed the Healthcare industry which returned -9.1% over the past year.

CBDS underperformed the Market in United States of America which returned 0.6% over the past year.


Share holder returns

CBDSIndustryMarket
7 Day-0.8%-0.04%-0.6%
30 Day-9.6%1.0%2.9%
90 Day-27.2%-1.5%1.3%
1 Year-80.4%-80.4%-7.7%-9.1%2.9%0.7%
3 Year-56.1%-56.1%29.6%24.3%44.6%35.2%
5 Year-85.0%-85.0%66.1%56.2%61.9%44.2%

Price Volatility Vs. Market

How volatile is Cannabis Sativa's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Cannabis Sativa undervalued based on future cash flows and its price relative to the stock market?

14.8x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Cannabis Sativa to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Cannabis Sativa to establish if it is available at substantial discount.


Price Based on Earnings

Cannabis Sativa is loss making, we can't compare its value to the US Healthcare industry average.

Cannabis Sativa is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Cannabis Sativa, we can't assess if its growth is good value.


Price Based on Value of Assets

Cannabis Sativa is overvalued based on assets compared to the US Healthcare industry average.


Next Steps

Future Growth

How is Cannabis Sativa expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cannabis Sativa has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of CBDS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Cannabis Sativa's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Cannabis Sativa performed over the past 5 years?

44.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Cannabis Sativa does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Cannabis Sativa's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Cannabis Sativa's 1-year growth to the US Healthcare industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Cannabis Sativa has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Cannabis Sativa has efficiently used its assets last year compared to the US Healthcare industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Cannabis Sativa improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Cannabis Sativa's financial position?


Financial Position Analysis

Cannabis Sativa's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Cannabis Sativa has no long term commitments.


Debt to Equity History and Analysis

Cannabis Sativa's level of debt (33%) compared to net worth is satisfactory (less than 40%).

Cannabis Sativa had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.3x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Cannabis Sativa has less than a year of cash runway based on current free cash flow.

Cannabis Sativa has less than a year of cash runway if free cash flow continues to grow at historical rates of 27% each year.


Next Steps

Dividend

What is Cannabis Sativa's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Cannabis Sativa's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Cannabis Sativa's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Cannabis Sativa has not reported any payouts.

Unable to verify if Cannabis Sativa's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Cannabis Sativa has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Cannabis Sativa's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

David Tobias (68yo)

0.7yrs

Tenure

0

Mr. David Tobias has been President of Cannabis Sativa, Inc., since March 29, 2016 and also serves as its Secretary. Mr. Tobias is a Director of EM Energy, Inc. He served as the Interim Chief Executive Off ...


Management Age and Tenure

2.3yrs

Average Tenure

67.5yo

Average Age

The tenure for the Cannabis Sativa management team is about average.


Board Age and Tenure

4.7yrs

Average Tenure

73yo

Average Age

The tenure for the Cannabis Sativa board of directors is about average.


Insider Trading

Cannabis Sativa individual insiders have only sold shares in the past 3 months, but not in substantial volumes.


Recent Insider Transactions

SellUS$23,26019 Aug 19
Donald Lundbom
EntityIndividual
Role
Chief Financial Officer
CFO & Chief Accounting Officer
Shares13,240
Max PriceUS$2.00
SellUS$14,23103 Jul 19
Donald Lundbom
EntityIndividual
Role
Chief Financial Officer
CFO & Chief Accounting Officer
Shares7,000
Max PriceUS$2.27
SellUS$295,90413 May 19
David Tobias
EntityIndividual
Shares121,827
Max PriceUS$2.91
SellUS$513 May 19
David Tobias
EntityIndividual
Shares2
Max PriceUS$2.58
SellUS$48,56906 May 19
Donald Lundbom
EntityIndividual
Role
Chief Financial Officer
CFO & Chief Accounting Officer
Shares16,808
Max PriceUS$3.00
SellUS$104,35114 Mar 19
Sadia Barrameda
EntityIndividual
Shares33,500
Max PriceUS$3.38
SellUS$193,10214 Mar 19
Sadia Barrameda
EntityIndividual
Shares59,240
Max PriceUS$3.61
SellUS$12,67913 Mar 19
Donald Lundbom
EntityIndividual
Role
Chief Financial Officer
CFO & Chief Accounting Officer
Shares4,000
Max PriceUS$3.18
SellUS$78,74405 Mar 19
Mike Gravel
EntityIndividual
Role
Member of the Board of Directors
Director
Shares25,000
Max PriceUS$3.16
SellUS$75,71201 Mar 19
Stephen Downing
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares24,628
Max PriceUS$3.16
SellUS$62,88826 Feb 19
David Tobias
EntityIndividual
Shares20,000
Max PriceUS$3.20
SellUS$7,20021 Feb 19
Mike Gravel
EntityIndividual
Role
Member of the Board of Directors
Director
Shares2,000
Max PriceUS$3.60
SellUS$70,44521 Feb 19
David Tobias
EntityIndividual
Shares20,500
Max PriceUS$3.59
SellUS$13,92708 Feb 19
Donald Lundbom
EntityIndividual
Role
Chief Financial Officer
CFO & Chief Accounting Officer
Shares3,845
Max PriceUS$3.70
SellUS$67,62808 Feb 19
David Tobias
EntityIndividual
Shares19,000
Max PriceUS$3.67
SellUS$247,30905 Feb 19
Sadia Barrameda
EntityIndividual
Shares71,400
Max PriceUS$4.19
SellUS$11,80805 Feb 19
Sadia Barrameda
EntityIndividual
Shares3,500
Max PriceUS$3.46
SellUS$71,12230 Jan 19
David Tobias
EntityIndividual
Shares19,500
Max PriceUS$3.85
SellUS$53,80717 Jan 19
David Tobias
EntityIndividual
Shares13,000
Max PriceUS$4.45
SellUS$30,86415 Jan 19
Donald Lundbom
EntityIndividual
Role
Chief Financial Officer
CFO & Chief Accounting Officer
Shares7,972
Max PriceUS$3.98
SellUS$32,14009 Jan 19
Donald Lundbom
EntityIndividual
Role
Chief Financial Officer
CFO & Chief Accounting Officer
Shares10,000
Max PriceUS$3.60
SellUS$12,00018 Dec 18
Donald Lundbom
EntityIndividual
Role
Chief Financial Officer
CFO & Chief Accounting Officer
Shares3,000
Max PriceUS$4.00
SellUS$11,14413 Dec 18
Deborah Goldsberry
EntityIndividual
Role
Member of the Board of Directors
Director
Shares2,844
Max PriceUS$3.92
SellUS$326,84911 Dec 18
Sadia Barrameda
EntityIndividual
Shares68,050
Max PriceUS$7.28
SellUS$13,31611 Dec 18
Sadia Barrameda
EntityIndividual
Shares4,000
Max PriceUS$3.33
SellUS$88,93701 Dec 18
David Tobias
EntityIndividual
Shares24,034
Max PriceUS$4.00
SellUS$77,75913 Nov 18
David Tobias
EntityIndividual
Shares16,050
Max PriceUS$5.10
SellUS$15,00013 Nov 18
Donald Lundbom
EntityIndividual
Role
Chief Financial Officer
CFO & Chief Accounting Officer
Shares3,000
Max PriceUS$5.00
SellUS$37,34526 Oct 18
David Tobias
EntityIndividual
Shares8,050
Max PriceUS$4.73
SellUS$145,66017 Oct 18
David Tobias
EntityIndividual
Shares27,600
Max PriceUS$5.70
SellUS$18,36009 Oct 18
David Tobias
EntityIndividual
Shares3,566
Max PriceUS$5.15
SellUS$241,43903 Oct 18
David Tobias
EntityIndividual
Shares45,700
Max PriceUS$5.71
SellUS$16,83403 Oct 18
Donald Lundbom
EntityIndividual
Role
Chief Financial Officer
CFO & Chief Accounting Officer
Shares3,000
Max PriceUS$5.61

Ownership Breakdown


Management Team

  • Don Lundbom (67yo)

    CFO & Chief Accounting Officer

    • Tenure: 2.3yrs
    • Compensation: US$344.34k
  • David Tobias (68yo)

    CEO, President

    • Tenure: 0.7yrs
  • Catherine Carroll (78yo)

    Treasurer & Director

    • Tenure: 6.2yrs
    • Compensation: US$362.86k
  • Carolyn Merrill (52yo)

    Controller

    • Tenure: 0yrs
    • Compensation: US$63.66k

Board Members

  • Steve Downing (80yo)

    Chairman of the Board

    • Tenure: 1.9yrs
  • Mike Gravel (89yo)

    Director

    • Tenure: 4.9yrs
    • Compensation: US$152.56k
  • David Tobias (68yo)

    CEO, President

    • Tenure: 0.7yrs
  • Catherine Carroll (78yo)

    Treasurer & Director

    • Tenure: 6.2yrs
    • Compensation: US$362.86k
  • Debby Goldsberry (52yo)

    Director

    • Tenure: 4.5yrs
  • Trevor Reed (55yo)

    Director

    • Tenure: 3.7yrs

Company Information

Cannabis Sativa, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cannabis Sativa, Inc.
  • Ticker: CBDS
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$27.234m
  • Shares outstanding: 22.14m
  • Website: https://cannabissativainc.com

Number of Employees


Location

  • Cannabis Sativa, Inc.
  • 1646 West Pioneer Boulevard
  • Suite 120
  • Mesquite
  • Nevada
  • 89027
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CBDSOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJul 2013
9C4MUN (Boerse Muenchen)YesCommon StockDEEURJul 2013

Biography

Cannabis Sativa, Inc., through its subsidiaries, develops, manufactures, and sells herbal based skin care products in the United States and internationally. The company offers Recover, a deep penetrating h ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/22 00:27
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.